Insmed's third quarter revenue of $524M beat estimates driven by strong BRINSUPRI momentum

Insmed reported third quarter 2026 results featuring a revenue beat and upwardly revised guidance for its primary commercial assets. Total revenue of $524.4 million grew significantly year-over-year, largely propelled by the rapid adoption of BRINSUPRI following its 2025 launch. While management raised the lower end of full-year revenue targets, the net loss of $0.46 per share was wider than the consensus estimate of $0.34 due to aggressive commercial and clinical scaling.

Key Highlights

• BRINSUPRI global revenue reached $400.1 million in the third quarter, representing a 29% sequential increase and exceeding analyst expectations of $382.7 million.
• Management raised the full-year 2026 revenue guidance for BRINSUPRI to $1.35B–$1.40B and for ARIKAYCE to $460M–$470M.
• Research and development expenses rose to $270.0 million, driven by manufacturing costs and clinical development for the TPIP program.
• The company maintained a robust balance sheet with $1.1 billion in cash and marketable securities, supporting its goal of reaching cash flow positivity in 2027.